ArticleImmunology2006
Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection.
Article in Immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Increased Heme Oxygenase 1 Expression upon a Primary Exposure to the Respiratory Syncytial Virus and a SecondaryAntioxidants (Basel, Switzerland) · 2022Article
- Review
- Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon.Tuberculosis (Edinburgh, Scotland) · 2020Article
- Type I interferons in tuberculosis: Foe and occasionally friend.The Journal of experimental medicine · 2018Review
- Impaired IFN-α-mediated signal in dendritic cells differentiates active from latent tuberculosis.PloS one · 2018Article
- cGAS-STING-TBK1-IRF3/7 induced interferon-β contributes to the clearing of non tuberculous mycobacterial infection in mice.Virulence · 2017Article
- Badger macrophages fail to produce nitric oxide, a key anti-mycobacterial effector molecule.Scientific reports · 2017Article
- Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences.Frontiers in immunology · 2017Review
- Target control of complex networks.Nature communications · 2014Article
- Disordered Toll-like receptor 2 responses in the pathogenesis of pulmonary sarcoidosis.Clinical and experimental immunology · 2013Article
- Interferon alpha treatment of patients with impaired interferon gamma signaling.Journal of clinical immunology · 2013Article
- Exacerbated type II interferon response drives hypervirulence and toxic shock by an emergent epidemic strain of Streptococcus suis.Infection and immunity · 2013Article
- Pattern recognition receptors and cytokines in Mycobacterium tuberculosis infection--the double-edged sword?BioMed research international · 2013Review
- Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- Genome-wide expression profiling identifies type 1 interferon response pathways in active tuberculosis.PloS one · 2012Article
- Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection.Cellular immunology · 2009Article
- Modulation of pulmonary dendritic cell function during mycobacterial infection.Infection and immunity · 2008Article
- Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency.European journal of pediatrics · 2007Article
- Modulation of naive CD4+ T-cell responses to an airway antigen during pulmonary mycobacterial infection.Infection and immunity · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
The role of type I interferon (IFN-alphabeta) in modulating innate or adaptive immune responses against mycobacterial infection in the lung is unclear. In this study we investigated the susceptibility of IFN-alphabeta-receptor-deficient (IFN-alphabetaR-/-) mice to pulmonary infection with aerosolized Mycobacterium bovis bacillus Calmette-Guérin (BCG). During early infection (2-3 weeks), enhanced growth of BCG was measured in the lungs of IFN-alphabetaR-/- mice compared to wild-type mice. However, during late infection the burden of BCG was similar in the lungs of IFN-alphabetaR-/- and wild-type mice. Although control of BCG growth was delayed, recruitment and activation of T and natural killer cells, production of IFN-gamma, and cytokine expression were all similar in wild-type and IFN-alphabetaR-/- mice. However, decreased expression of nitric oxide in bronchoalveolar lavage fluids from IFN-alphabetaR-/- mice correlated with enhanced growth of BCG. Bone marrow-derived macrophages from IFN-alphabetaR-/- mice also produced less nitric oxide following infection with BCG in vitro. These findings suggest that IFN-alphabeta contributes to innate immunity to pulmonary mycobacterial infection by augmenting production of nitric oxide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.